Literature DB >> 25707572

A reactive oxygen species-mediated loop maintains increased expression of NADPH oxidases 2 and 4 in skin fibroblasts from patients with systemic sclerosis.

Tatiana Spadoni1, Silvia Svegliati Baroni1, Donatella Amico1, Lisa Albani1, Gianluca Moroncini1, Enrico V Avvedimento2, Armando Gabrielli1.   

Abstract

OBJECTIVE: Reactive oxygen species (ROS) contribute to the pathogenesis of fibrosis in systemic sclerosis (SSc; scleroderma), and NADPH oxidase (NOX) is an important source of ROS. Since the role of single NOX isoforms has not been previously investigated in SSc, this study was undertaken to assess the expression of NOX in SSc fibroblasts compared to normal healthy cells and to analyze their role in cell activation.
METHODS: Expression of NOX isoforms in dermal fibroblasts from patients with SSc and healthy control subjects was analyzed by real-time polymerase chain reaction, immunoblotting, and immunofluorescence. NOX isoforms were silenced using small interfering RNA. Production of ROS was measured by fluorometry and confocal microscopy.
RESULTS: Scleroderma fibroblasts showed up-regulation of NOX-2 and NOX-4 protein and messenger RNA (mRNA) expression. Treatment of the cells with diphenyleneiodonium, a nonselective inhibitor of flavin-containing enzymes, and silencing of NOX2 and NOX4 decreased the production of ROS as well as the expression of type I collagen and α-smooth muscle actin in SSc fibroblasts. ROS generated by NOX-2 and NOX-4 were involved in DNA damage and activation of a DNA repair checkpoint. Incubation of healthy control fibroblasts with platelet-derived growth factor (PDGF) or with IgG isolated from SSc patient serum enhanced the expression of NOX2 and NOX4 mRNA, via ROS, in a time-dependent manner. Treatment with actinomycin D, a transcription inhibitor, reversed the effects of PDGF stimulation but not the effects of SSc IgG.
CONCLUSION: Both NOX2 and NOX4 generate ROS in SSc fibroblasts and play a critical role in cell activation and DNA damage. Expression of NOX-2 and NOX-4 in SSc fibroblasts is maintained by a ROS-mediated loop.
© 2015, American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25707572     DOI: 10.1002/art.39084

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  25 in total

Review 1.  Therapeutic potential of NADPH oxidase 1/4 inhibitors.

Authors:  G Teixeira; C Szyndralewiez; S Molango; S Carnesecchi; F Heitz; P Wiesel; J M Wood
Journal:  Br J Pharmacol       Date:  2016-07-14       Impact factor: 8.739

2.  Getting to the core of fibrosis: targeting redox imbalance in aging.

Authors:  Louise Hecker; Victor J Thannickal
Journal:  Ann Transl Med       Date:  2016-03

Review 3.  Systemic sclerosis-associated fibrosis: an accelerated aging phenotype?

Authors:  Tracy R Luckhardt; Victor J Thannickal
Journal:  Curr Opin Rheumatol       Date:  2015-11       Impact factor: 5.006

4.  Abrogation of transforming growth factor-β-induced tissue fibrosis in mice with a global genetic deletion of Nox4.

Authors:  Peter J Wermuth; Fabian A Mendoza; Sergio A Jimenez
Journal:  Lab Invest       Date:  2018-11-23       Impact factor: 5.662

5.  Increased expression of NAPDH oxidase 4 in systemic sclerosis dermal fibroblasts: regulation by transforming growth factor β.

Authors:  Sonsoles Piera-Velazquez; Alma Makul; Sergio A Jiménez
Journal:  Arthritis Rheumatol       Date:  2015-10       Impact factor: 10.995

6.  Dermal delivery of HSP47 siRNA with NOX4-modulating mesoporous silica-based nanoparticles for treating fibrosis.

Authors:  Jingga Morry; Worapol Ngamcherdtrakul; Shenda Gu; Shaun M Goodyear; David J Castro; Moataz M Reda; Thanapon Sangvanich; Wassana Yantasee
Journal:  Biomaterials       Date:  2015-07-10       Impact factor: 12.479

Review 7.  Sirtuins and Accelerated Aging in Scleroderma.

Authors:  Anne E Wyman; Sergei P Atamas
Journal:  Curr Rheumatol Rep       Date:  2018-03-17       Impact factor: 4.592

Review 8.  Emerging drugs for the treatment of scleroderma: a review of recent phase 2 and 3 trials.

Authors:  David Roofeh; Alain Lescoat; Dinesh Khanna
Journal:  Expert Opin Emerg Drugs       Date:  2020-10-26       Impact factor: 4.191

Review 9.  Endothelial to Mesenchymal Transition (EndoMT) in the Pathogenesis of Human Fibrotic Diseases.

Authors:  Sonsoles Piera-Velazquez; Fabian A Mendoza; Sergio A Jimenez
Journal:  J Clin Med       Date:  2016-04-11       Impact factor: 4.241

Review 10.  Vascular Remodelling and Mesenchymal Transition in Systemic Sclerosis.

Authors:  Pier Andrea Nicolosi; Enrico Tombetti; Norma Maugeri; Patrizia Rovere-Querini; Silvia Brunelli; Angelo A Manfredi
Journal:  Stem Cells Int       Date:  2016-03-16       Impact factor: 5.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.